Rapha Capital Management
VC Fund
Florida, United States
Rapha Capital Management is a VC fund in Florida focused on Health Care and Therapeutics. Rapha Capital Management focused on identifying and growing revolutionary ideas in medicine, healthcare and technology before others can see their value. For inquiries, telephone and contact details are used.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 50%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Rapha Capital Management invests in
Health CareTherapeuticsBiotechnologyPharmaceuticalGenetics
Stages Rapha Capital Management invests in
Series ASeries CPost-IPO DebtPost-IPO EquityConvertible Note
Countries Rapha Capital Management invests in
United StatesIsrael
Round sizes
Series A $5.3M–$35MPost-IPO Debt $3M–$7.3M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Series A
- $5.3M–$35M
- Post-IPO Debt
- $3M–$7.3M
Investment Focus
Industry
- Health Care 3 (30%)
- Therapeutics 3 (30%)
- Biotechnology 3 (30%)
- Pharmaceutical 2 (20%)
- Genetics 1 (10%)
Stage
- Series A 2 (20%)
- Series C 1 (10%)
- Post-IPO Debt 1 (10%)
- Post-IPO Equity 1 (10%)
- Convertible Note 1 (10%)
Country
- United States 4 (40%)
- Israel 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Kevin Slawin
Founder and Managing Partner
|
Founder and Managing Partner | Total investments: 1 | Find email | |
Kevin Slawin
Founder and Managing Partner
|
Founder and Managing Partner | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Pulmatrix
|
Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaledanti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes. | $19M / Post-IPO Equity / Mar 26, 2026 | |
FIZE Medical
|
Fize Medical offers novel tools for reliable, monitoring of patient, its initial solution is a way to track renal output continuously. | $14M / Series A / Dec 24, 2024 | |
AsclepiX Therapeutics
|
AsclepiX Therapeutics represents the next generation of biologics and drug development technology. They use bioinformatics and systems biology methods to design classes of short biomimetic anti-angiogenic (anti-neovascular), and anti-lymphangiogenic peptides. They also use the latest developments in biomaterials and drug delivery to designlong-lasting biodegradable nano and microparticles to deliver these biomimetic therapeutic peptides throughout the body.AsclepiX Therapeutics utilizes its platform technology for indications in ophthalmology, oncology, and for other angiogenesis and lymphangiogenesis-dependent diseases. | $10M / Series A / Jul 26, 2023 | |
Imagin Medical
|
Imagin Medical is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive surgeries. The Company’s initial focus is bladder cancer.The i/Blue Imaging System™ is expected to dramatically improve physicians’ ability to visualize cancerous cells. Working in conjunction withfluorescing imaging agents, this advanced, ultrasensitive imaging technology combines sophisticated opto-electronic functions and near-infrared fluorescence to deliver images far superior to conventional white light systems. Display options include separate blue or white light images, blue and white images displayed side-by-side, or a blending of the blue and white light images into one. Imagin believes the time savings will increase the efficiency of the operating room and potentially reduce healthcare costs by enabling procedures to be performed in the less expensive physician’s office.The i/Blue system was invented by Dr. Stavros Demos at the Lawrence Livermore National Laboratory (LLNL) and validated in collaboration with the UC Davis Comprehensive Cancer Center and Dr. Ralph deVere White, one of the world’s leading authorities on bladder cancer. Imagin now holds the exclusive license to this intellectual property and relocated the final stage of development to the highly-regarded University of Rochester Laboratory for Laser Energetics (LLE) and its affiliated first-class Medical Center. A Research Study using the i/Blue Imaging System prototype was led by Dr. Edward Messing and provided valuable input to the development of the final product for commercialization. Imagin’s engineering team has completed the Proof of Concept Phase and expects the Functional Phase to be completed by end of 2Q2019.As the i/Blue Imaging System becomes established in the urology market, the Company will complete development of the i/Vision Imaging System technology which combines multiple illumination sources into one system. The i/Vision will accommodate the most commonly used fluorescing contrast agents and will potentially enable Imagin to expand into additional surgical specialties. | $7.3M / Post-IPO Debt / Aug 22, 2022 | |
|
Imagin Medical
|
Imagin Medical is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive surgeries. The Company’s initial focus is bladder cancer.The i/Blue Imaging System™ is expected to dramatically improve physicians’ ability to visualize cancerous cells. Working in conjunction withfluorescing imaging agents, this advanced, ultrasensitive imaging technology combines sophisticated opto-electronic functions and near-infrared fluorescence to deliver images far superior to conventional white light systems. Display options include separate blue or white light images, blue and white images displayed side-by-side, or a blending of the blue and white light images into one. Imagin believes the time savings will increase the efficiency of the operating room and potentially reduce healthcare costs by enabling procedures to be performed in the less expensive physician’s office.The i/Blue system was invented by Dr. Stavros Demos at the Lawrence Livermore National Laboratory (LLNL) and validated in collaboration with the UC Davis Comprehensive Cancer Center and Dr. Ralph deVere White, one of the world’s leading authorities on bladder cancer. Imagin now holds the exclusive license to this intellectual property and relocated the final stage of development to the highly-regarded University of Rochester Laboratory for Laser Energetics (LLE) and its affiliated first-class Medical Center. A Research Study using the i/Blue Imaging System prototype was led by Dr. Edward Messing and provided valuable input to the development of the final product for commercialization. Imagin’s engineering team has completed the Proof of Concept Phase and expects the Functional Phase to be completed by end of 2Q2019.As the i/Blue Imaging System becomes established in the urology market, the Company will complete development of the i/Vision Imaging System technology which combines multiple illumination sources into one system. The i/Vision will accommodate the most commonly used fluorescing contrast agents and will potentially enable Imagin to expand into additional surgical specialties. | $3M / Post-IPO Debt / Aug 30, 2021 | |
|
FIZE Medical
|
Fize Medical offers novel tools for reliable, monitoring of patient, its initial solution is a way to track renal output continuously. | $5.3M / Series A / Apr 06, 2021 | |
|
FIZE Medical
|
Fize Medical offers novel tools for reliable, monitoring of patient, its initial solution is a way to track renal output continuously. | $5.3M / Series A / Apr 06, 2021 | |
|
AsclepiX Therapeutics
|
AsclepiX Therapeutics represents the next generation of biologics and drug development technology. They use bioinformatics and systems biology methods to design classes of short biomimetic anti-angiogenic (anti-neovascular), and anti-lymphangiogenic peptides. They also use the latest developments in biomaterials and drug delivery to designlong-lasting biodegradable nano and microparticles to deliver these biomimetic therapeutic peptides throughout the body.AsclepiX Therapeutics utilizes its platform technology for indications in ophthalmology, oncology, and for other angiogenesis and lymphangiogenesis-dependent diseases. | $35M / Series A / Jun 24, 2020 | |
Poseida Therapeutics
|
Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our coreproprietary platforms, including our non-viral piggyBac DNA Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. | $142M / Series C / Apr 22, 2019 | |
|
AsclepiX Therapeutics
|
AsclepiX Therapeutics represents the next generation of biologics and drug development technology. They use bioinformatics and systems biology methods to design classes of short biomimetic anti-angiogenic (anti-neovascular), and anti-lymphangiogenic peptides. They also use the latest developments in biomaterials and drug delivery to designlong-lasting biodegradable nano and microparticles to deliver these biomimetic therapeutic peptides throughout the body.AsclepiX Therapeutics utilizes its platform technology for indications in ophthalmology, oncology, and for other angiogenesis and lymphangiogenesis-dependent diseases. | $5M / Convertible Note / Nov 13, 2018 |
Co-Investors
Perceptive Advisors
3 deals together
Barer & Son Capital
2 deals together
Mendham Investment Group
2 deals together
Aisling Capital
1 deal together
Boxer Capital
1 deal together
eHealth Ventures
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Health Care Investors in United States
21,541 investors
Biotech Investors in United States
11,011 investors
Biotechnology Angel Investors
2,354 investors
FAQ
What does Rapha Capital Management invest in?
Rapha Capital Management invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A and Series C stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Rapha Capital Management's check size?
Rapha Capital Management typically joins rounds of $5.3M–$35M at Series A and $3M–$7.3M at Post-IPO Debt. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Rapha Capital Management participates in.
How do I contact Rapha Capital Management?
Public channels for Rapha Capital Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Rapha Capital Management?
The team at Rapha Capital Management includes Kevin Slawin (Founder and Managing Partner) and Kevin Slawin (Founder and Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
